BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY

https://storage.unitedwebnetwork.com/files/1099/02f6c869fa3b7c1bbba59f0b8d8746cb.pdf
BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY
HernĂ¡n
Trimarchi
Jonathan Barratt jb81@leicester.ac.uk University of Leicester Department of Cardiovascular Sciences, Renal Medicine Leicester
Jai Radhakrishnan jr55@cumc.columbia.edu Columbia University Irving Medical Center Nephrology Division New York
Dana V. Rizk drizk@uab.edu University of Alabama at Birmingham Division of Nephrology Birmingham
Bess Sorensen bsorensen@chinooktx.com Chinook Therapeutics, a Novartis Company Biostatistics Seattle
Jocelyn Leiske jleiske@chinooktx.com Chinook Therapeutics, a Novartis Company Portfolio Strategy Seattle
Zeeshan Khawaja zkhawaja@chinooktx.com Chinook Therapeutics, a Novartis Company Clinical Development Seattle
Kirk Campbell kirk.campbell@mssm.edu Icahn School of Medicine at Mount Sinai Division of Nephrology New York
Vlado Perkovic vlado.perkovic@unsw.edu.au University of New South Wales The George Institute for Global Health Sydney
 
 
 
 
 
 
 
E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos